The focus of this review was to summarize the relationship between 1H MRS metabolites and biomarkers acquired through PET (tau, amyloid), biofluid, and postmortem AD pathology analysis across the AD continuum in the brain (Table 1). Here, MAPT is linked to Alzheimer disease.